Advertisement
ALGN vs DXCM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and DXCM is a Hold.
Momentum Indicator for ALGN turns positive, indicating new upward trend
ALGN saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 59 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALGN's RSI Oscillator exited the oversold zone, 27 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +4.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 192 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
ALGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.434) is normal, around the industry mean (5.011). P/E Ratio (25.174) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
DXCM in downward trend: 10-day moving average broke below 50-day moving average on October 06, 2026
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 58 cases where DXCM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on DXCM as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on October 16, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 204 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.484) is normal, around the industry mean (10.930). P/E Ratio (34.261) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ALGN | DXCM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 27 | |
PRICE GROWTH RATING 1..100 | 59 | 18 | |
P/E GROWTH RATING 1..100 | 25 | 72 | |
SEASONALITY SCORE 1..100 | n/a | 27 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (63) in the Medical Specialties industry is in the same range as DXCM (82). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that DXCM’s stock grew somewhat faster than ALGN’s over the last 12 months.
DXCM's Price Growth Rating (18) in the Medical Specialties industry is somewhat better than the same rating for ALGN (59). This means that DXCM’s stock grew somewhat faster than ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (25) in the Medical Specialties industry is somewhat better than the same rating for DXCM (72). This means that ALGN’s stock grew somewhat faster than DXCM’s over the last 12 months.
| ALGN | DXCM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | N/A |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 74% |
| Advances ODDS (%) | 2 days ago 70% | 9 days ago 68% |
| Declines ODDS (%) | 12 days ago 75% | 3 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 53% |
| Aroon ODDS (%) | 1 day ago 78% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green while DXCM’s FA Score has 2 green FA rating(s).
- ALGN’s FA Score: 1 green, 4 red.
- DXCM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while DXCM’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 4 bearish.
- DXCM’s TA Score: 5 bullish, 3 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +3.22% price change this week, while DXCM (@Medical/Nursing Services) price change was +2.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.71%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +3.30%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.10%. For the same industry, the average monthly price growth was -8.07%, and the average quarterly price growth was -16.10%.
Reported Earning Dates
ALGN is expected to report earnings on Oct 28, 2026.
DXCM is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.71% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-6.10% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement